Fig. 4: Shmt1 and shmt2 expression in patients during lung cancer progression. | Cell Death & Disease

Fig. 4: Shmt1 and shmt2 expression in patients during lung cancer progression.

From: Cytosolic serine hydroxymethyltransferase controls lung adenocarcinoma cells migratory ability by modulating AMP kinase activity

Fig. 4

A Analysis of shmt1 and shmt2 related to patient pathological stage represented with the violin plots, Log2 (TPM + 1) for log scale. B shmt1 and shmt2 gene expression in lung adenocarcinoma with metastasis vs. lung squamous cell carcinoma with metastasis. C shmt1 and shmt2 gene expression in metastatic sites of different tumors from GSE18549 series45. Data are expressed as log2 RMA signal intensity. GSM461786, GSM461788, GSM461790, lung adenocarcinoma (primary site) to brain (metastatic site); GSM461783, breast carcinoma to brain; GSM461785, colon adenocarcinoma to brain; GSM461787, esophageal adenocarcinoma to brain; GSM461789, colorectal adenocarcinoma to brain; GSM461791, breast mucinous adenocarcinoma to brain. D Pearson correlation analysis of SHMT1 as log2(TPM) and of SLC6A9, SLC1A4 and SLC1A5 in Lung adenocarcinoma (LUAD). P value cutoff = 0.001. Data from TGCA and GTEx. One-way ANOVA and Student’s t test were used for statistical analysis (ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.005).

Back to article page